Michael S. Hofman - Concepedia

Author

Michael S. Hofman

Also Known As

HOFMAN, MICHAEL, Hofman, Michael, Hofman, Michael S., M HOFMAN, M Hofman, M S Hofman, M. Hofman, M. S. Hofman, M.S. Hofman, Michael Hofman

531

Publications

25.2K

Citations

H-Index

112

Concepts

All Affiliations

Peter MacCallum Cancer Centre The University of Melbourne Monash University St Vincent's Hospital Sydney The University of Sydney

About

Michael S. Hofman is an author at Peter MacCallum Cancer Centre specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	38	65	8.6K
2	Health Sciences	24	36	4.2K
3	Engineering	10	10	547
4	Public Health	2	2	164
5	Nursing	1	1	27

Michael S. Hofman

174

Publications

17.2K

Citations

H-Index

Page 1

	Year	Citations
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study Michael S. Hofman, Nathan Lawrentschuk, Roslyn J. Francis, The Lancet UrologySurgical OncologyHigh-risk Prostate CancerGenitourinary CancerOncologic Imaging	2020	1.8K
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study Michael S. Hofman, John Violet, Rodney J. Hicks, The Lancet Oncology	2018	1.1K
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial Michael S. Hofman, Louise Emmett, Shahneen Sandhu, The Lancet UrologyOncologyGenitourinary CancerMedicineClinical Trials	2021	1K
Somatostatin Receptor Imaging with<sup>68</sup>Ga DOTATATE PET/CT: Clinical Utility, Normal Patterns, Pearls, and Pitfalls in Interpretation Michael S. Hofman, Eddie Lau, Rodney J. Hicks Radiographics	2015	537
Dosimetry of <sup>177</sup>Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes John Violet, Price Jackson, Justin Ferdinandus, Journal of Nuclear Medicine	2018	454
18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial Jérémie Calais, Francesco Ceci, Matthias Eiber, The Lancet Oncology Positron Emission TomographyUrologySurgical OncologyComparative Imaging TrialMedical Imaging	2019	452
The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study Louise Emmett, James P Buteau, Nathan Papa, European Urology Additive Diagnostic ValueUrologyMedical ImagingCancer DetectionDiagnosis	2021	394
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019 Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, European Urology	2020	384
E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET Francesco Ceci, Daniela E. Oprea‐Lager, Louise Emmett, European Journal of Nuclear Medicine and Molecular Imaging	2021	338
Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial Shankar Siva, Mathias Bressel, Declan G. Murphy, European Urology Adaptive RadiotherapyUrologySurgical OncologyRadiation TherapyMedicine	2018	313

Page 1